APO Research
Talk to an analyst

APO RESEARCH · REPORT

Central Nervous System (CNS) Stimulant Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Central Nervous System (CNS) Stimulant Drugs Industry Growth and Trends Forecast to 2032

20 December 2025117 pages

Choose your research edition.

Industry ResearchCentral Nervous System (CNS) Stimulant Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Central Nervous System (CNS) Stimulant Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Central Nervous System (CNS) Stimulant Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Central Nervous System (CNS) Stimulant Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Central Nervous System (CNS) Stimulant Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Central Nervous System (CNS) Stimulant Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Central Nervous System (CNS) Stimulant Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Central Nervous System (CNS) Stimulant Drugs include Takeda Pharmaceuticals, Sanofi, Thermo Fisher Scientific, Johnson and Johnson, Novartis, Merck, Roche, Eli Lilly and Company and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Central Nervous System (CNS) Stimulant Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Central Nervous System (CNS) Stimulant Drugs market size, estimates, and forecasts are presented in terms of sales volume (tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Central Nervous System (CNS) Stimulant Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Central Nervous System (CNS) Stimulant Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Central Nervous System (CNS) Stimulant Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Central Nervous System (CNS) Stimulant Drugs Market by Company

Takeda Pharmaceuticals

Sanofi

Thermo Fisher Scientific

Johnson and Johnson

Novartis

Merck

Roche

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Biogen

Shire

Perdue Pharma

Celltech

Astellas Pharma

Central Nervous System (CNS) Stimulant Drugs Segment by Type

Cocaine

Caffeine

Amphetamine

Others

Central Nervous System (CNS) Stimulant Drugs Segment by Application

Attention Deficit Hyperactivity Disorder (ADHD)

Narcolepsy

Others

Central Nervous System (CNS) Stimulant Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Stimulant Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Stimulant Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Stimulant Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Central Nervous System (CNS) Stimulant Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Central Nervous System (CNS) Stimulant Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Cocaine Table 2. Major Company of Caffeine Table 3. Major Company of Amphetamine Table 4. Major Company of Others Table 5. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 7. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Type (2021-2026) Table 8. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (US$ Million) Table 9. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Type (2021-2026) Table 10. Global Central Nervous System (CNS) Stimulant Drugs Price by Type (2021-2026) & (US$/ton) Table 11. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (tons) Table 12. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Type (2027-2032) Table 13. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (US$ Million) Table 14. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Type (2027-2032) Table 15. Global Central Nervous System (CNS) Stimulant Drugs Price by Type (2027-2032) & (US$/ton) Table 16. North America Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 17. North America Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 19. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 21. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 23. Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 25. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Central Nervous System (CNS) Stimulant Drugs Industry Trends Table 27. Central Nervous System (CNS) Stimulant Drugs Industry Drivers Table 28. Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges Table 29. Central Nervous System (CNS) Stimulant Drugs Industry Restraints Table 30. Global Central Nervous System (CNS) Stimulant Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Company (2021-2026) Table 32. Global Central Nervous System (CNS) Stimulant Drugs Sales by Company (2021-2026) & (tons) Table 33. Global Central Nervous System (CNS) Stimulant Drugs Sales Share by Company (2021-2026) Table 34. Global Central Nervous System (CNS) Stimulant Drugs Market Price by Company (2021-2026) & (US$/ton) Table 35. Global Central Nervous System (CNS) Stimulant Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Central Nervous System (CNS) Stimulant Drugs Major Company Production Sites and Headquarters Table 37. Global Central Nervous System (CNS) Stimulant Drugs Company, Product Type & Application Table 38. Global Central Nervous System (CNS) Stimulant Drugs Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Central Nervous System (CNS) Stimulant Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Central Nervous System (CNS) Stimulant Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2026) & (tons) Table 43. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Region (2021-2026) Table 44. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2026) & (US$ Million) Table 45. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Region (2021-2026) Table 46. Global Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 47. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2027-2032) & (tons) Table 48. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Region (2027-2032) Table 49. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2027-2032) & (US$ Million) Table 50. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Region (2027-2032) Table 51. Global Central Nervous System (CNS) Stimulant Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2027-2032) Table 52. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 54. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Application (2021-2026) Table 55. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (US$ Million) Table 56. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Application (2021-2026) Table 57. Global Central Nervous System (CNS) Stimulant Drugs Price by Application (2021-2026) & (US$/ton) Table 58. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (tons) Table 59. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Application (2027-2032) Table 60. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (US$ Million) Table 61. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Application (2027-2032) Table 62. Global Central Nervous System (CNS) Stimulant Drugs Price by Application (2027-2032) & (US$/ton) Table 63. North America Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 64. North America Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 66. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 68. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 70. Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 72. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Takeda Pharmaceuticals Company Information Table 74. Takeda Pharmaceuticals Business Overview Table 75. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 76. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 77. Takeda Pharmaceuticals Recent Development Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 81. Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 82. Sanofi Recent Development Table 83. Thermo Fisher Scientific Company Information Table 84. Thermo Fisher Scientific Business Overview Table 85. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 86. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 87. Thermo Fisher Scientific Recent Development Table 88. Johnson and Johnson Company Information Table 89. Johnson and Johnson Business Overview Table 90. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 91. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 92. Johnson and Johnson Recent Development Table 93. Novartis Company Information Table 94. Novartis Business Overview Table 95. Novartis Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 96. Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 97. Novartis Recent Development Table 98. Merck Company Information Table 99. Merck Business Overview Table 100. Merck Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 101. Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 102. Merck Recent Development Table 103. Roche Company Information Table 104. Roche Business Overview Table 105. Roche Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 106. Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 107. Roche Recent Development Table 108. Eli Lilly and Company Company Information Table 109. Eli Lilly and Company Business Overview Table 110. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 111. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 112. Eli Lilly and Company Recent Development Table 113. Pfizer Company Information Table 114. Pfizer Business Overview Table 115. Pfizer Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 116. Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 117. Pfizer Recent Development Table 118. GlaxoSmithKline Company Information Table 119. GlaxoSmithKline Business Overview Table 120. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 121. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 122. GlaxoSmithKline Recent Development Table 123. Biogen Company Information Table 124. Biogen Business Overview Table 125. Biogen Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 126. Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 127. Biogen Recent Development Table 128. Shire Company Information Table 129. Shire Business Overview Table 130. Shire Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 131. Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 132. Shire Recent Development Table 133. Perdue Pharma Company Information Table 134. Perdue Pharma Business Overview Table 135. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 136. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 137. Perdue Pharma Recent Development Table 138. Celltech Company Information Table 139. Celltech Business Overview Table 140. Celltech Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 141. Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 142. Celltech Recent Development Table 143. Astellas Pharma Company Information Table 144. Astellas Pharma Business Overview Table 145. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 146. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 147. Astellas Pharma Recent Development Table 148. North America Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 149. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 150. North America Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2026) Table 151. North America Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032) & (tons) Table 152. North America Central Nervous System (CNS) Stimulant Drugs Sales Market Share Forecast by Country (2027-2032) Table 153. North America Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026) & (US$ Million) Table 155. North America Central Nervous System (CNS) Stimulant Drugs Market Share by Country (2021-2026) Table 156. North America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America Central Nervous System (CNS) Stimulant Drugs Market Share Forecast by Country (2027-2032) Table 158. Europe Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 159. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 160. Europe Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2026) Table 161. Europe Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032) & (tons) Table 162. Europe Central Nervous System (CNS) Stimulant Drugs Sales Market Share Forecast by Country (2027-2032) Table 163. Europe Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe Central Nervous System (CNS) Stimulant Drugs Market Share by Country (2021-2026) Table 166. Europe Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe Central Nervous System (CNS) Stimulant Drugs Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 170. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2026) Table 171. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032) & (tons) Table 172. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026) & (US$ Million) Table 175. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Share by Country (2021-2026) Table 176. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Share Forecast by Country (2027-2032) Table 178. Latin America Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 179. Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 180. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2026) Table 181. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032) & (tons) Table 182. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Market Share Forecast by Country (2027-2032) Table 183. Latin America Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Latin America Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026) & (US$ Million) Table 185. Latin America Central Nervous System (CNS) Stimulant Drugs Market Share by Country (2021-2026) Table 186. Latin America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Latin America Central Nervous System (CNS) Stimulant Drugs Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 190. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2021-2026) Table 191. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032) & (tons) Table 192. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026) & (US$ Million) Table 195. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Share by Country (2021-2026) Table 196. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Share Forecast by Country (2027-2032) Table 198. Key Raw Materials Table 199. Raw Materials Key Suppliers Table 200. Central Nervous System (CNS) Stimulant Drugs Distributors List Table 201. Central Nervous System (CNS) Stimulant Drugs Customers List Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. Central Nervous System (CNS) Stimulant Drugs Image Figure 2. Global Central Nervous System (CNS) Stimulant Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Central Nervous System (CNS) Stimulant Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Central Nervous System (CNS) Stimulant Drugs Sales (2021-2032) & (tons) Figure 5. Cocaine Image Figure 6. Global Cocaine Sales YoY Growth (2021-2032) & (tons) Figure 7. Caffeine Image Figure 8. Global Caffeine Sales YoY Growth (2021-2032) & (tons) Figure 9. Amphetamine Image Figure 10. Global Amphetamine Sales YoY Growth (2021-2032) & (tons) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (tons) Figure 13. Global Central Nervous System (CNS) Stimulant Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Central Nervous System (CNS) Stimulant Drugs Market Share by Type 2025 VS 2032 Figure 15. North America Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Type in 2025 Figure 16. North America Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Type in 2025 Figure 17. Europe Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Europe Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Type in 2025 Figure 21. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Central Nervous System (CNS) Stimulant Drugs Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Attention Deficit Hyperactivity Disorder (ADHD) Image Figure 28. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales YoY Growth (2021-2032) & (tons) Figure 29. Narcolepsy Image Figure 30. Global Narcolepsy Sales YoY Growth (2021-2032) & (tons) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (tons) Figure 33. Global Central Nervous System (CNS) Stimulant Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Central Nervous System (CNS) Stimulant Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 46. North America Central Nervous System (CNS) Stimulant Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Central Nervous System (CNS) Stimulant Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 50. Europe Central Nervous System (CNS) Stimulant Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Central Nervous System (CNS) Stimulant Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 54. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 58. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Central Nervous System (CNS) Stimulant Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 62. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Central Nervous System (CNS) Stimulant Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Central Nervous System (CNS) Stimulant Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Cocaine
  • Caffeine
  • Amphetamine
  • Others
Applications
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Narcolepsy
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Sanofi
  • Thermo Fisher Scientific
  • Johnson and Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Shire
  • Perdue Pharma
  • Celltech
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Central Nervous System (CNS) Stimulant Drugs Market by Type
  6. 1.3.1 Cocaine
  7. 1.3.2 Caffeine
  8. 1.3.3 Amphetamine
  9. 1.3.4 Others
  10. 1.4 Global Central Nervous System (CNS) Stimulant Drugs Market Size by Type
  11. 1.4.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Central Nervous System (CNS) Stimulant Drugs Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Central Nervous System (CNS) Stimulant Drugs Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Central Nervous System (CNS) Stimulant Drugs Industry Trends
  2. 2.2 Central Nervous System (CNS) Stimulant Drugs Industry Drivers
  3. 2.3 Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges
  4. 2.4 Central Nervous System (CNS) Stimulant Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Central Nervous System (CNS) Stimulant Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Central Nervous System (CNS) Stimulant Drugs Price (2021-2026)
  4. 3.4 Global Central Nervous System (CNS) Stimulant Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Central Nervous System (CNS) Stimulant Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Central Nervous System (CNS) Stimulant Drugs Company, Product Type & Application
  7. 3.7 Global Central Nervous System (CNS) Stimulant Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Central Nervous System (CNS) Stimulant Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Central Nervous System (CNS) Stimulant Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Central Nervous System (CNS) Stimulant Drugs Tier 1, Tier 2, and Tier 3
4 Central Nervous System (CNS) Stimulant Drugs Regional Status and Outlook
  1. 4.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Central Nervous System (CNS) Stimulant Drugs Historic Market Size by Region
  3. 4.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Central Nervous System (CNS) Stimulant Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Central Nervous System (CNS) Stimulant Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Central Nervous System (CNS) Stimulant Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Central Nervous System (CNS) Stimulant Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Central Nervous System (CNS) Stimulant Drugs by Application
  1. 5.1 Central Nervous System (CNS) Stimulant Drugs Market by Application
  2. 5.1.1 Attention Deficit Hyperactivity Disorder (ADHD)
  3. 5.1.2 Narcolepsy
  4. 5.1.3 Others
  5. 5.2 Global Central Nervous System (CNS) Stimulant Drugs Market Size by Application
  6. 5.2.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Central Nervous System (CNS) Stimulant Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Central Nervous System (CNS) Stimulant Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda Pharmaceuticals
  2. 6.1.1 Takeda Pharmaceuticals Company Information
  3. 6.1.2 Takeda Pharmaceuticals Business Overview
  4. 6.1.3 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  6. 6.1.5 Takeda Pharmaceuticals Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Thermo Fisher Scientific
  14. 6.3.1 Thermo Fisher Scientific Company Information
  15. 6.3.2 Thermo Fisher Scientific Business Overview
  16. 6.3.3 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  18. 6.3.5 Thermo Fisher Scientific Recent Developments
  19. 6.4 Johnson and Johnson
  20. 6.4.1 Johnson and Johnson Company Information
  21. 6.4.2 Johnson and Johnson Business Overview
  22. 6.4.3 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  24. 6.4.5 Johnson and Johnson Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 Merck
  32. 6.6.1 Merck Company Information
  33. 6.6.2 Merck Business Overview
  34. 6.6.3 Merck Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  36. 6.6.5 Merck Recent Developments
  37. 6.7 Roche
  38. 6.7.1 Roche Company Information
  39. 6.7.2 Roche Business Overview
  40. 6.7.3 Roche Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  42. 6.7.5 Roche Recent Developments
  43. 6.8 Eli Lilly and Company
  44. 6.8.1 Eli Lilly and Company Company Information
  45. 6.8.2 Eli Lilly and Company Business Overview
  46. 6.8.3 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  48. 6.8.5 Eli Lilly and Company Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 GlaxoSmithKline
  56. 6.10.1 GlaxoSmithKline Company Information
  57. 6.10.2 GlaxoSmithKline Business Overview
  58. 6.10.3 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  60. 6.10.5 GlaxoSmithKline Recent Developments
  61. 6.11 Biogen
  62. 6.11.1 Biogen Company Information
  63. 6.11.2 Biogen Business Overview
  64. 6.11.3 Biogen Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  66. 6.11.5 Biogen Recent Developments
  67. 6.12 Shire
  68. 6.12.1 Shire Company Information
  69. 6.12.2 Shire Business Overview
  70. 6.12.3 Shire Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  72. 6.12.5 Shire Recent Developments
  73. 6.13 Perdue Pharma
  74. 6.13.1 Perdue Pharma Company Information
  75. 6.13.2 Perdue Pharma Business Overview
  76. 6.13.3 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  78. 6.13.5 Perdue Pharma Recent Developments
  79. 6.14 Celltech
  80. 6.14.1 Celltech Company Information
  81. 6.14.2 Celltech Business Overview
  82. 6.14.3 Celltech Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  84. 6.14.5 Celltech Recent Developments
  85. 6.15 Astellas Pharma
  86. 6.15.1 Astellas Pharma Company Information
  87. 6.15.2 Astellas Pharma Business Overview
  88. 6.15.3 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  90. 6.15.5 Astellas Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Central Nervous System (CNS) Stimulant Drugs Sales by Country
  2. 7.1.1 North America Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  6. 7.2.1 North America Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country
  2. 8.1.1 Europe Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  6. 8.2.1 Europe Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Central Nervous System (CNS) Stimulant Drugs Sales by Country
  2. 10.1.1 South America Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  6. 10.2.1 South America Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Central Nervous System (CNS) Stimulant Drugs Value Chain Analysis
  2. 12.1.1 Central Nervous System (CNS) Stimulant Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Central Nervous System (CNS) Stimulant Drugs Production Mode & Process
  7. 12.2 Central Nervous System (CNS) Stimulant Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Central Nervous System (CNS) Stimulant Drugs Distributors
  10. 12.2.3 Central Nervous System (CNS) Stimulant Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst